HALB CEO, CTO and YSU's Dr. Sturrus Discuss CDC, Research Discoveries etc., on "The Street Reports Podcasts" Listen Now!
Halberd Corporation (OTC PINK:HALB) recently featured President & CEO William A. Hartman, Chief Technical Officer Dr. Mitchell S. Felder, and YSU Professor Dr. Wm. Gregg Sturrus in an interview on 'The Street Reports.' They discussed significant strides in research aimed at eradicating antibiotic-resistant bacteria and harmful fungi supplied by the CDC.
The laser eradication technique, led by Dr. Sturrus, has successfully neutralized various pathogenic strains. Dr. Felder emphasized that no tested pathogens have developed resistance to this extracorporeal method. Additionally, Halberd has initiated pre-clinical testing for a nasal spray designed to mitigate head trauma effects. Hartman expressed optimism about advancing this research into viable therapeutic solutions for chronic diseases and injuries.
- Successful eradication of antibiotic-resistant bacteria and fungi through laser technology.
- Pre-clinical testing for a nasal spray to address head trauma commenced at Mississippi State University.
- No pathogens tested to date have developed resistance to the laser eradication methodology.
- None.
JACKSON CENTER, PA / ACCESSWIRE / April 20, 2023 / Halberd Corporation's (OTC PINK:HALB) President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S. Felder, and Youngstown State University (YSU) Professor/lead researcher, Dr. Wm. Gregg Sturrus were interviewed on "The Street Reports" to discuss the company's latest research discoveries and progress on eradicating CDC (Centers for Disease Control and Prevention) provided antibiotic resistant bacteria and deadly fungi.
Listen here: https://thestreetreports.com/halbs-ceo-cto-and-ysus-dr-sturrus-discuss-cdc-research-discoveries-etc-on-the-street-reports-podcasts-listen-now/
Dr. W. Gregg Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences Department at YSU, is spearheading the laser eradication work, and spoke about the actual lab work and progress in the control of laboratory variables resulting in the successful eradication of various strains of very toxic, antibiotic resistant, bacteria and deadly Candida auris fungi supplied by the CDC.
Dr. Mitchell S. Felder, Chief Technology Officer of Halberd Corporation and inventor of the patented and patent-pending extracorporeal technologies employed by Halberd, provided information on the theoretical basis for the methodology - to physically remove the pathophysiologic basis of the disease without antibiotics. Halberd's experience reveals that no bacteria or pathogen tested to date has develop a resistance to the laser eradication methodology. By employing the laser eradication process extracorporeally, outside the body, it is designed to safely and effectively eliminate disease-causing pathogens without the dangerous side-effects associated with injected or ingested medications.
Dr. Felder also provided information on the recent start of pre-clinical testing at Mississippi State University of Halberd's patent-pending nasal spray intended to block the negative effects of head trauma. The objective is to be able to administer the nasal spray within two hours after head trauma to avoid or minimize long-term brain damage.
William A. Hartman, Chairman, President & CEO, indicated he is most excited about the prospects of developing a product from a proof-of-concept state to a fully functioning therapeutic solution to some of what are considered today's "incurable" diseases and otherwise irreversible consequences of head trauma.
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC
The Street Reports
The Street Reports discovering companies from "Wall Street 2 Bay Street" specializes in bringing relevant information on micro-cap, small-cap, and generally undervalued companies to the attention readers/listeners which maybe potential investors.
About Youngstown State University
Youngstown State University is a public university in Youngstown, Ohio, and is composed of 5 undergraduate colleges. The University has over 150 undergraduate degree programs and 50 graduate degree programs serving over 12,000 students in studies up to the doctoral level. Beyond its current student body, the university has more than 125,000 alumni across the country and around the world.
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/750275/HALB-CEO-CTO-and-YSUs-Dr-Sturrus-Discuss-CDC-Research-Discoveries-etc-on-The-Street-Reports-Podcasts-Listen-Now
FAQ
What recent developments has Halberd Corporation announced regarding antibiotic-resistant bacteria?
What is the focus of the nasal spray being developed by Halberd Corporation?
Who participated in the recent interview by Halberd Corporation on 'The Street Reports'?
What are the prospects for Halberd's research on diseases considered 'incurable'?
What are Halberd Corporation's primary products and methodologies?
